P. Cheema

发表

A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408

R. Advani, R. Gascoyne, J. Winter, 2020, Clinical Cancer Research.

Panitumumab monotherapy in patients with metastatic colorectal cancer and cetuximab infusion reactions: a series of four case reports.

E. Mitchell, P. Cheema, M. Shing, 2009, Clinical colorectal cancer.

Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin.

A. Verma, J. Maciejewski, J. Bennett, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immunomodulatory drug costimulates T cells via the B7-CD28 pathway.

N. Munshi, P. Richardson, N. Mitsiades, 2004, Blood.

Immmunomodulatory Drug (Revamid) Co-stimulates T cells via The B7-CD28 pathway

N. Munshi, P. Richardson, N. Mitsiades, 2003 .

Institutional experiences with panitumumab monotherapy in metastatic colorectal cancer (mCRC) patients (pts) intolerant to cetuximab

E. Mitchell, P. Cheema, M. Shing, 2007 .

A phase II prospective trial correlating progression-free survival (PFS) with CYP2D6 activity in patients with metastatic breast cancer treated with tamoxifen: ECOG-ACRIN E3108.

Minetta C. Liu, G. Sledge, D. Moore, 2016 .

Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102.

J. Manola, B. Ramaswamy, A. Wolff, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor – Positive , Human Epidermal Growth Factor Receptor 2 – Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy : Results of PrE 0102

J. Manola, B. Ramaswamy, A. Wolff, 2018 .

Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOG‐ACRIN Cancer Research Group (E4203)

P. Catalano, A. Benson, J. Grem, 2018, Cancer.

A 3-Arm Randomized Phase II Trial with Bendamustine/Rituximab Therapy in Untreated High Risk (HR) Follicular Lymphoma (FL): Bortezomib Induction or Novel IMiD® Continuation (BIONIC) Study from the ECOG-ACRIN Cancer Research Group

R. Advani, R. Gascoyne, J. Winter, 2017 .

Effect of bortezomib on complete remission (CR) rate when added to bendamustine-rituximab (BR) in previously untreated high-risk (HR) follicular lymphoma (FL): A randomized phase II trial of the ECOG-ACRIN Cancer Research Group (E2408).

R. Advani, R. Gascoyne, T. Habermann, 2016 .